SEC Form 4 · accession 0001250853-16-000138
IOVANCE BIOTHERAPEUTICS, INC. · IOVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Lotze
Officer — Chief Scientific Officer
Period of report
Mar 28, 2016
Accepted (ET)
Mar 30, 2016 · 7:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001425205
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.54 | Mar 28, 2016 | A | 225,000 | A | — | Mar 28, 2026 | Common Stock | 225,000 | 225,000 | D |
Explanation of responses
- F1The option will vest as to 22,500 shares on March 28, 2017, as to 33,750 shares on March 28, 2018, and as to 56,250 shares on March 28, 2019. The remaining shares will vest upon achieving certain milestones, and all vesting is contingent upon the Reporting Person still providing services to the Issuer on the respective dates.